Tourmaline Bio Signs Deal for Acquisition by Novartis AG

Written by Emily J. Thompson, Senior Investment Analyst

TRML%

Source: Newsfilter

Updated: Sep 09 2025

0mins

Source: Newsfilter

Acquisition Announcement: Novartis is set to acquire Tourmaline Bio for $48.00 per share, totaling approximately $1.4 billion, reflecting a 59% premium over Tourmaline's stock price prior to the announcement.
Potential of Pacibekitug: The acquisition highlights the promise of Tourmaline's pacibekitug, an anti-IL-6 monoclonal antibody aimed at treating cardiovascular diseases, with expectations for completion in the fourth quarter of 2025, pending regulatory approvals.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Tourmaline Bio Signs Deal for Acquisition by Novartis AG

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Oracle Corporation Faces Investigation Over Misleading Statements, Shares Drop 4.3%

Velan Inc. (VLN) Shareholder Sells 72.1% Stake for C$203.9 Million

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch